The Rehabilitation of Oncological @entity1 Presenting XXXX .

@entity1 @entity6220 @entity5 @entity16 @entity1897 @entity158 @entity9
The International Association for the Study of @entity158 (IASP 2011) defines @entity9 as "the @entity158 caused by an @entity16 ". The central @entity9 is defined as "the @entity158 caused by an @entity6220 ", whereas the peripheral @entity9 is defined as "the @entity158 caused by an @entity1897 " [1]. The @entity1897 describes any affection of the peripheral nervous system. The etiology is vast, there being a number of over 100 possible causes, which causes the global morbidity rate to reach approximately 2.4%. The chronic nature of the @entity158 superposes the everyday routine and leads to the high intake of medication for @entity158 alleviation. The number of cases of neuroplasia has always increased today. This disturbing diagnosis which can potentiate the signs and symptoms of @entity1897 as well as reduce and limit the treatment options associated with @entity16 . The treatment presupposes a multidisciplinary approach, while the solution to prevent complications involves the control of risk factors and pathophysiological treatment. @entity1897 ( @entity1897 ) is a significant disabling symptom that is tightly connected to the administration of neurotoxic cytostatic agents used for the treatment of @entity5 . @entity1897 compromises the quality of life and produces @entity158 or discomfort [2]. I have sought to produce a presentation of the medicated and physical-kinetic treatment options that have proved their effectiveness during clinical studies or random trials and can be applied to @entity5 @entity1 presenting with symptoms associated with @entity1897 , namely with @entity9 , and support it with arguments.
